THOUSAND OAKS, Calif.—Amgen announced July 15 that it has named Jonathan M. Peacock as its new chief financial officer.
Peacock will be responsible for Amgen's finance and investor relations operations and will report to Kevin W. Sharer, Amgen's chairman and CEO. He will be succeeding Michael A. Kelly, who served as acting CFO since May 2010.
Peacock, 52, joins Amgen from Novartis Pharmaceutical AG, where he served as CFO and administration officer since 2005. In that role, Peacock led the finance, information technology, purchasing, strategic planning and mergers and acquisitions functions.
Previously, Peacock was a partner at McKinsey and Company, where he was co-leader of the European corporate finance practice working in the consulting firm's Amsterdam, Zurich and London offices. He also was a partner at Price Waterhouse in New York and London. He has an MA degree in Economics from the University of St. Andrews in Scotland and is a chartered accountant.
"I am delighted to have a leader of Jonathan's talent, vision and international experience join Amgen at a time when we are expanding globally," said Sharer.
